Beyond LRP1 suppression, experimental data indicate that PCSK9 could contribute to cancer progression by promoting epithelial–mesenchymal transition (EMT), activating the PI3K/AKT signalling pathway, and influencing macrophage polarisation toward pro-inflammatory and pro-metastatic phenotypes [182]. Here, PCSK9 is linked to cancer.